A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 11, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Urothelial CarcinomaSolid Tumor

Interventions

DRUG

BL-B01D1

Administration by intravenous infusion

DRUG

SI-B003

Administration by intravenous infusion

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY